References:
1. Martelli M, Ferreri A, Di Rocco A, Ansuinelli M, Johnson PWM. Primary mediastinal large B-cell lymphoma. Crit Rev Oncol Hematol . May 2017;113:318-327. doi:10.1016/j.critrevonc.2017.01.009
2. Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.The New England journal of medicine . Apr 11 2013;368(15):1408-16. doi:10.1056/NEJMoa1214561
3. Katsanis E, Sapp LN, Varner N, Koza S, Stea B, Zeng Y. Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide/Bendamustine in Pediatric and Young Adult Patients with Hematologic Malignancies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation . Oct 2018;24(10):2034-2039. doi:10.1016/j.bbmt.2018.06.007
4. Katsanis E, Maher K, Roe D, Simpson RJ. Progressive substitution of post-transplant cyclophosphamide with bendamustine: A phase I study in haploidentical bone marrow transplantation. eJHaem May 26, 2020 2020;1(May 26):1-7. doi:10.1002/jha2.20
5. Katsanis E, Sapp LN, Reid SC, Reddivalla N, Stea B. T-Cell Replete Myeloablative Haploidentical Bone Marrow Transplantation Is an Effective Option for Pediatric and Young Adult Patients With High-Risk Hematologic Malignancies. Front Pediatr . 2020;8:282. doi:10.3389/fped.2020.00282
6. Giulino-Roth L. How I treat primary mediastinal B-cell lymphoma.Blood . Aug 23 2018;132(8):782-790. doi:10.1182/blood-2018-04-791566
7. Giulino-Roth L, O’Donohue T, Chen Z, et al. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. British journal of haematology . Dec 2017;179(5):739-747. doi:10.1111/bjh.14951
8. Zinzani PL, Pellegrini C, Chiappella A, et al. Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. Blood . Apr 20 2017;129(16):2328-2330. doi:10.1182/blood-2017-01-764258
9. Zinzani PL, Ribrag V, Moskowitz CH, et al. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood . Jul 20 2017;130(3):267-270. doi:10.1182/blood-2016-12-758383
10. Kohorst MA, Nunez CA, Tewari P, et al. Primary mediastinal large B-cell lymphoma in paediatric and adolescent patients: emerging questions in the era of immunotherapy. British journal of haematology . May 29 2020;doi:10.1111/bjh.16761
11. Herrera AF, Chen L, Khajavian S, et al. Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation . Dec 2019;25(12):2383-2387. doi:10.1016/j.bbmt.2019.07.041
12. Schoch LK, Cooke KR, Wagner-Johnston ND, et al. Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv . Sep 11 2018;2(17):2226-2229. doi:10.1182/bloodadvances.2018019208
13. Zeidan AM, Forde PM, Symons H, et al. HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation . Mar 2014;20(3):314-8. doi:10.1016/j.bbmt.2013.11.020
14. Goebeler ME, Knop S, Viardot A, et al. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology . Apr 1 2016;34(10):1104-11. doi:10.1200/JCO.2014.59.1586
15. Durer S, Durer C, Shafqat M, et al. Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: a case report with literature review. Immunotherapy . Apr 2019;11(5):373-378. doi:10.2217/imt-2018-0104